Literature DB >> 26661695

Assessment of PAX6 alleles in 66 families with aniridia.

A M Bobilev1, M E McDougal2, W L Taylor3, E E Geisert4, P A Netland3, J D Lauderdale1,2.   

Abstract

We report on PAX6 alleles associated with a clinical diagnosis of classical aniridia in 81 affected individuals representing 66 families. Allelic variants expected to affect PAX6 function were identified in 61 families (76 individuals). Ten cases of sporadic aniridia (10 families) had complete (8 cases) or partial (2 cases) deletion of the PAX6 gene. Sequence changes that introduced a premature termination codon into the open reading frame of PAX6 occurred in 47 families (62 individuals). Three individuals with sporadic aniridia (three families) had sequence changes (one deletion, two run-on mutations) expected to result in a C-terminal extension. An intronic deletion of unknown functional significance was detected in one case of sporadic aniridia (one family), but not in unaffected relatives. Within these 61 families, single nucleotide substitutions accounted for 30/61 (49%), indels for 23/61 (38%), and complete deletion of the PAX6 locus for 8/61 (13%). In five cases of sporadic aniridia (five families), no disease-causing mutation in the coding region was detected. In total, 23 unique variants were identified that have not been reported in the Leiden Open Variation Database (LOVD) database. Within the group assessed, 92% had sequence changes expected to reduce PAX6 function, confirming the primacy of PAX6 haploinsufficiency as causal for aniridia.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  absent iris; chromosome 11p13; eye abnormalities; eye disease; irideremia

Mesh:

Substances:

Year:  2016        PMID: 26661695      PMCID: PMC4873406          DOI: 10.1111/cge.12708

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  75 in total

1.  Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  Estimate of the mutation rate per nucleotide in humans.

Authors:  M W Nachman; S L Crowell
Journal:  Genetics       Date:  2000-09       Impact factor: 4.562

3.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms.

Authors:  R Sachidanandam; D Weissman; S C Schmidt; J M Kakol; L D Stein; G Marth; S Sherry; J C Mullikin; B J Mortimore; D L Willey; S E Hunt; C G Cole; P C Coggill; C M Rice; Z Ning; J Rogers; D R Bentley; P Y Kwok; E R Mardis; R T Yeh; B Schultz; L Cook; R Davenport; M Dante; L Fulton; L Hillier; R H Waterston; J D McPherson; B Gilman; S Schaffner; W J Van Etten; D Reich; J Higgins; M J Daly; B Blumenstiel; J Baldwin; N Stange-Thomann; M C Zody; L Linton; E S Lander; D Altshuler
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

4.  Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.

Authors:  Cheryl Y Gregory-Evans; Xia Wang; Kishor M Wasan; Jinying Zhao; Andrew L Metcalfe; Kevin Gregory-Evans
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

5.  Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.

Authors:  M Wilschanski; L L Miller; D Shoseyov; H Blau; J Rivlin; M Aviram; M Cohen; S Armoni; Y Yaakov; T Pugatsch; T Pugatch; M Cohen-Cymberknoh; N L Miller; A Reha; V J Northcutt; S Hirawat; K Donnelly; G L Elfring; T Ajayi; E Kerem
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

Review 6.  Aniridia with a heterozygous PAX6 mutation in which the pituitary function was partially impaired.

Authors:  Naoki Shimo; Tetsuyuki Yasuda; Tetsuhiro Kitamura; Kenji Matsushita; Saeko Osawa; Yuichi Yamamoto; Junji Kozawa; Michio Otsuki; Tohru Funahashi; Akihisa Imagawa; Hideaki Kaneto; Kohji Nishida; Iichiro Shimomura
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

7.  3' deletions cause aniridia by preventing PAX6 gene expression.

Authors:  J D Lauderdale; J S Wilensky; E R Oliver; D S Walton; T Glaser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

8.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Eitan Kerem; Michael W Konstan; Kris De Boeck; Frank J Accurso; Isabelle Sermet-Gaudelus; Michael Wilschanski; J Stuart Elborn; Paola Melotti; Inez Bronsveld; Isabelle Fajac; Anne Malfroot; Daniel B Rosenbluth; Patricia A Walker; Susanna A McColley; Christiane Knoop; Serena Quattrucci; Ernst Rietschel; Pamela L Zeitlin; Jay Barth; Gary L Elfring; Ellen M Welch; Arthur Branstrom; Robert J Spiegel; Stuart W Peltz; Temitayo Ajayi; Steven M Rowe
Journal:  Lancet Respir Med       Date:  2014-05-15       Impact factor: 30.700

9.  Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Authors:  Katharine Bushby; Richard Finkel; Brenda Wong; Richard Barohn; Craig Campbell; Giacomo P Comi; Anne M Connolly; John W Day; Kevin M Flanigan; Nathalie Goemans; Kristi J Jones; Eugenio Mercuri; Ros Quinlivan; James B Renfroe; Barry Russman; Monique M Ryan; Mar Tulinius; Thomas Voit; Steven A Moore; H Lee Sweeney; Richard T Abresch; Kim L Coleman; Michelle Eagle; Julaine Florence; Eduard Gappmaier; Allan M Glanzman; Erik Henricson; Jay Barth; Gary L Elfring; Allen Reha; Robert J Spiegel; Michael W O'donnell; Stuart W Peltz; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2014-10       Impact factor: 3.217

10.  PAX6 mutation in association with ptosis, cataract, iris hypoplasia, corneal opacification and diabetes: a new variant of familial aniridia?

Authors:  Neena M Peter; Martin Leyland; Hardeep S Mudhar; Jo Lowndes; Katharine R Owen; Helen Stewart
Journal:  Clin Exp Ophthalmol       Date:  2013-05-03       Impact factor: 4.207

View more
  13 in total

1.  Characterization of Associated Nonclassical Phenotypes in Patients with Deletion in the WAGR Region Identified by Chromosomal Microarray: New Insights and Literature Review.

Authors:  Vanessa Sodré de Souza; Gabriela Corassa Rodrigues da Cunha; Beatriz R Versiani; Claudiner Pereira de Oliveira; Maria Teresa Alves Silva Rosa; Silviene F de Oliveira; Patricia N Moretti; Juliana F Mazzeu; Aline Pic-Taylor
Journal:  Mol Syndromol       Date:  2022-02-11

Review 2.  Relative Frequencies of PAX6 Mutational Events in a Russian Cohort of Aniridia Patients in Comparison with the World's Population and the Human Genome.

Authors:  Tatyana A Vasilyeva; Andrey V Marakhonov; Sergey I Kutsev; Rena A Zinchenko
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  Novel PAX6 mutation reported in an aniridia patient.

Authors:  Andrew Winegarner; Yoshinori Oie; Satoshi Kawasaki; Nozomi Nishida; Kohji Nishida
Journal:  Hum Genome Var       Date:  2017-12-07

4.  Structural brain abnormalities in 12 persons with aniridia.

Authors:  Madison K Grant; Anastasia M Bobilev; Jordan E Pierce; Jon DeWitte; James D Lauderdale
Journal:  F1000Res       Date:  2017-03-13

5.  Morphometric analysis of the lens in human aniridia and mouse Small eye.

Authors:  Anna Voskresenskaya; Nadezhda Pozdeyeva; Yevgeniy Batkov; Tatyana Vasilyeva; Andrey Marakhonov; Richard A West; Jeffrey L Caplan; Ales Cvekl; Yan Wang; Melinda K Duncan
Journal:  Exp Eye Res       Date:  2020-11-26       Impact factor: 3.467

6.  PAX6 molecular analysis and genotype-phenotype correlations in families with aniridia from Australasia and Southeast Asia.

Authors:  Emmanuelle Souzeau; Adam K Rudkin; Andrew Dubowsky; Robert J Casson; James S Muecke; Erica Mancel; Mark Whiting; Richard A D Mills; Kathryn P Burdon; Jamie E Craig
Journal:  Mol Vis       Date:  2018-03-28       Impact factor: 2.367

7.  Molecular analysis of Cypriot families with aniridia reveals a novel PAX6 mutation.

Authors:  Andreas Syrimis; Nayia Nicolaou; Angelos Alexandrou; Ioannis Papaevripidou; Michael Nicolaou; Eleni Loukianou; Carolina Sismani; Stavros Malas; Violetta Christophidou-Anastasiadou; George A Tanteles
Journal:  Mol Med Rep       Date:  2018-06-05       Impact factor: 2.952

8.  Parental Mosaicism in PAX6 Causes Intra-Familial Variability: Implications for Genetic Counseling of Congenital Aniridia and Microphthalmia.

Authors:  María Tarilonte; Matías Morín; Patricia Ramos; Marta Galdós; Fiona Blanco-Kelly; Cristina Villaverde; Dolores Rey-Zamora; Gema Rebolleda; Francisco J Muñoz-Negrete; Saoud Tahsin-Swafiri; Blanca Gener; Miguel-Angel Moreno-Pelayo; Carmen Ayuso; Manuela Villamar; Marta Corton
Journal:  Front Genet       Date:  2018-10-17       Impact factor: 4.599

Review 9.  The genetic architecture of aniridia and Gillespie syndrome.

Authors:  Hildegard Nikki Hall; Kathleen A Williamson; David R FitzPatrick
Journal:  Hum Genet       Date:  2018-09-22       Impact factor: 4.132

10.  Mutation spectrum of PAX6 and clinical findings in 95 Chinese patients with aniridia.

Authors:  Bing You; Xiaohui Zhang; Ke Xu; Yue Xie; Hanwen Ye; Yang Li
Journal:  Mol Vis       Date:  2020-03-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.